EUVIMEDEUVIMED entdecken
Open Access

The impact of genetic risk on the prevalence of advanced fibrosis and cirrhosis in prospectively assessed patients with type 2 diabetes

Lana Bridi, Saaket Agrawal, Kaleb Tesfai, Egbert Madamba, Ricki Bettencourt, Lisa M Richards, Amit V Khera, Rohit Loomba iD, Veeral Ajmera iD

Alimentary Pharmacology & Therapeutics · 2024

DOI: 10.1111/apt.18099 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2024. Verfasst von Lana Bridi und 8 weiteren Autor:innen. Beteiligte Einrichtung: MASLD Research Center, Division of Gastroenterology, University of California San Diego, La Jolla, California, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Liver Cirrhosis, Elasticity Imaging Techniques. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, NIDDK NIH HHS, Gilead Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Genetic factors contribute to the risk and severity of metabolic dysfunction‐associated steatotic liver disease (MASLD). However, the utility of genetic testing in risk stratification remains poorly characterised.

Aims

To examine the influence of genetic risk on advanced fibrosis and cirrhosis in patients with type 2 diabetes mellitus (T2DM) and the utility of a polygenic risk score (PRS) in screening guidelines.

Methods

We prospectively enrolled adults aged ≥50 years with T2DM recruited from clinics. PRS was the sum of risk alleles in PNPLA3 , TM6SF2 and SERPINA1 minus the protective variant in HSD17B13 . We performed magnetic resonance elastography and vibration‐controlled transient elastography to assess for advanced fibrosis and cirrhosis.

Results

Of 382 included patients, the mean age and BMI were 64.8 (±8.4) years and 31.7 (±6.2) kg/m 2 respectively. The prevalence of advanced fibrosis and cirrhosis were 12.3% and 5.2% respectively; higher PRS was associated with increased risk of cirrhosis (2.7% vs. 7.5%, p = 0.037). High PRS was associated with increased risk of advanced fibrosis among those with fibrosis‐4 index (FIB‐4) index

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Liver CirrhosisElasticity Imaging TechniquesHumansMiddle AgedMaleFemaleAgedProspective StudiesPrevalenceGenetic Predisposition to DiseaseMembrane ProteinsRisk FactorsLipaseNon-alcoholic Fatty Liver DiseaseRisk AssessmentAcyltransferasesalpha 1-Antitrypsin17-Hydroxysteroid DehydrogenasesPhospholipases A2, Calcium-Independent

Substanzen

Membrane ProteinsLipaseTM6SF2 protein, humanPNPLA3 protein, humanSERPINA1 protein, humanHSD17B13 protein, humanAcyltransferasesalpha 1-Antitrypsin17-Hydroxysteroid DehydrogenasesPhospholipases A2, Calcium-Independent

Autor:innen und Institutionen

  • MASLD Research Center, Division of Gastroenterology, University of California San Diego, La Jolla, California, USA.
  • Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
  • Division of Cardiology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Verve Therapeutics, Boston, Massachusetts, USA.
  • Division of Gastroenterology, University of California San Diego, La Jolla, California, USA.

ORCID-Profile: Rohit Loomba, Veeral Ajmera

Förderung

  • NCATS NIH HHS
  • NIDDK NIH HHS
  • Gilead Sciences
  • John C Martin Foundation
  • NHLBI NIH HHS
  • National Heart, Lung, and Blood Institute
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Center for Advancing Translational Sciences

Zitieren

APA

Bridi, L., Agrawal, S., Tesfai, K., Madamba, E., Bettencourt, R., Richards, L. M., Khera, A. V., Loomba, R., & Ajmera, V. (2024). The impact of genetic risk on the prevalence of advanced fibrosis and cirrhosis in prospectively assessed patients with type 2 diabetes. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18099

Vancouver

Bridi L, Agrawal S, Tesfai K, Madamba E, Bettencourt R, Richards LM, et al. The impact of genetic risk on the prevalence of advanced fibrosis and cirrhosis in prospectively assessed patients with type 2 diabetes. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.18099

BibTeX
@article{Bridi2024,
  author = {Bridi, Lana and Agrawal, Saaket and Tesfai, Kaleb and Madamba, Egbert and Bettencourt, Ricki and Richards, Lisa M and Khera, Amit V and Loomba, Rohit and Ajmera, Veeral},
  title = {The impact of genetic risk on the prevalence of advanced fibrosis and cirrhosis in prospectively assessed patients with type 2 diabetes},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1111/apt.18099}
}
Kostenlos starten →